ReviewDiabetology & metabolic syndrome2018

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

Rodrigo Oliveira Moreira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.